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Abstract
Many oral mucosal conditions cause considerable and prolonged pain that to date has been difficult 
to alleviate via topical delivery, and the use of injection causes many patients dental anxiety and 
needle-prick pain. Therefore, developing a non-injectable drug delivery system as an alternative 
administration procedure may vastly improve the health and wellbeing of these patients. Recent 
advances in the development of mucoadhesive electrospun patches for the direct delivery of 
therapeutics to the oral mucosa offer a potential solution, but as yet, the release of local anaesthetics 
from this system and their uptake by oral tissue has not been demonstrated. Here, we demonstrate 
the fabrication of lidocaine-loaded electrospun fibre patches, drug release, and subsequent uptake 
and permeation through porcine buccal mucosa. Lidocaine HCl and lidocaine base were incorporated 
into the electrospun patches to evaluate the difference in drug permeation for the two drug 
compositions.  Lidocaine released from the lidocaine HCl-containing electrospun patches was 
significantly quicker than from the lidocaine base patches, with double the amount of drug released 
from the lidocaine HCl patches in the first 15 minutes (0.16 ± 0.04 mg) compared to from the lidocaine 
base patches (0.07 ± 0.01 mg). The permeation of lidocaine from the lidocaine HCl electrospun patches 
through ex vivo porcine buccal mucosa was also detected in 15 minutes, whereas permeation of 
lidocaine from the lidocaine base patch was not detected. Matrix-assisted laser desorption ionisation 
 mass spectrometry imaging (MALDI-MSI) was used to investigate localisation of lidocaine within oral 
tissue. Lidocaine in solution as well as from the mucoadhesive patch penetrated into buccal mucosal 
tissue in a time-dependent manner and was detectable in the lamina propria after only 15 minutes. 
Moreover, the lidocaine released from lidocaine HCl electrospun patches retained biological activity, 
inhibiting veratridine-mediated opening of voltage-gated sodium channels in SH-SY5Y neuroblastoma 
cells. These data suggest that a mucoadhesive electrospun patch may be used as a vehicle for rapid 
uptake and sustained anaesthetic drug delivery to treat or prevent oral pain.
Keywords: Electrospinning, lidocaine, oral mucosa, ex vivo tissue permeation, MALDI-mass 
spectrometry imaging, drug distribution in tissue
Introduction
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Control of pain is a major unmet clinical need in a range of oral conditions including mucositis, 
ulceration and trauma 1,2. The effects of pain may be so severe as to affect eating, drinking, speech or 
sleep 3. Pain is also associated with a number of dental procedures and is most commonly alleviated 
by the injection of a local anaesthetic. Unfortunately, the use of injection is a major factor in dental 
anxiety and non-attendance at clinic 4. A wide range of technologies to alleviate localised pain in the 
oral cavity have been investigated, including tablets, films, gels and mouth washes 510. These are 
chiefly based on topical delivery of drugs, but all current approaches have limitations related to the 
very challenging conditions found within the oral cavity, where salivary flow and tissue movement 
contribute to a hostile mechanical and chemical environment.
We have recently fabricated an electrospun patch with mucoadhesive properties with the potential 
to deliver drugs to oral lesions for a sustained period 11. The patch displays good adhesion to oral 
tissues and is well tolerated with no significant cytotoxicity or irritation in both a porcine model and 
healthy volunteers 12. Delivery of clobetasol-17-propionate was demonstrated in a tissue engineered 
oral mucosal model and in ex vivo porcine mucosa 12. Electrospinning can create relatively thin-fibre 
(typically 100 nm to 50 D fibre diameter) patches, where the polymer and solvent selection, as well 
as the electrospinning conditions, may alter the mechanical properties of the mat and its behaviour in 
the oral cavity 13. These electrospun patches have high mucoadhesive properties due to the high 
surface area to volume ratio and to the incorporation of a hygroscopic polymer that rapidly adsorbs 
saliva at the site of application leading to rapid and prolonged drug release 11,14. This innovative 
medical device has considerable potential for the site-specific delivery of pain relieving drugs such as 
non-steroidal anti-inflammatories or local anaesthetics 12,15.
Lidocaine HCl is a relatively safe and effective anaesthetic and the most commonly used in local 
oromucosal pain relief 16. A number of ex vivo studies evaluating the transbuccal permeation of 
lidocaine, applied as either a solution or gel have been reported 17,18. However, electrospun patches 
have not been subject to detailed investigation of transbuccal delivery of lidocaine. Porcine mucosa is 
frequently used in transbuccal permeation experiments since it is physiologically similar to that of 
humans, and is therefore considered the gold standard for modelling oral drug delivery 19. Ex vivo 
permeation studies provide quantitative data, however to visualise the spatial distribution of drugs in 
tissue, mass spectrometry imaging (MSI) may be used. MSI allows for a multitude of compounds to be 
detected including the drug, metabolites, excipients and endogenous compounds such as lipids, which 
may serve as tissue biomarkers. There are a number of different MSI techniques, with matrix-assisted 
laser desorption ionisation (MALDI) MSI being one of the most commonly used 20. The method 
requires deposition of a matrix on the tissue sample to aid the ionisation of analytes when targeted 
by the laser. The process is relatively non-destructive and therefore the tissue sample can be stained 
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using haematoxylin and eosin for histological evaluation after the process. We have previously used 
MALDI-MSI to examine permeation of nicotine across porcine buccal mucosa 21,22, and a similar 
experimental setup was used in this study to determine the time-dependent permeation of lidocaine.
Herein, we demonstrate for the first time the targeted permeation of lidocaine into ex vivo porcine 
buccal mucosa released from mucoadhesive electrospun patches to be used as a local oromucosal 
drug delivery vehicle. Both lidocaine HCl and lidocaine base were successfully incorporated into the 
electrospun patches, for which the release, ex vivo permeation, and bioactivity were measured. Our 
findings show a greater release of lidocaine HCl from the electrospun patches compared to lidocaine 
base and only lidocaine permeation from the lidocaine HCl patches was detected ex vivo. Additionally, 
using MALDI-MSI, the localisation and time-dependent penetration of the drug within tissue was 
established. This study shows that lidocaine-loaded electrospun patches deliver functionally active 
drug directly to buccal mucosa in a therapeutically useful timeframe. This drug delivery device has the 
potential of improving the control of localised oral pain that is currently a major unmet clinical 
problem. 
Methods
Materials
Poly(vinylpyrrolidone) (PVP) (MW 2000 kDa) and Eudragit RS100 (MW 30 kDa) were kindly donated by 
BASF (UK) and Evonik Industries AG (Germany), respectively. Poly(caprolactone) (PCL) (MW 80 kDa), 
poly(ethylene oxide) (PEO) (MW 400 kDa), trifluoroacetic acid (TFA, 99 %), 2,5-dihydroxybenzanoic acid 
(DHB, 98 %), carboxymethylcellulose (CMC), potassium dihydrogen phosphate, disodium hydrogen 
phosphate, sodium hydroxide, alcoholic eosin Y solution,  haematoxylin solution Mayers, fetal calf 
serum, non-essential amino acids, penicillin, streptomycin, ethylenediaminetetraacetic acid (EDTA), 
dimethylsulfoxide (DMSO) were purchased from Sigma Aldrich (UK&DK). Lidocaine HCl (MW 270.8 Da), 
lidocaine (MW 234.3 Da) and veratridine were purchased from Abcam (UK). Solvents ethanol (K 99.8 
%), dichloromethane (DCM, K 99 %), dimethylformamide (DMF, 99.98 %) and acetonitrile (ACN, K 99.9 
%), media DMEM/Hams F12 with L-Glutamine and Fluo-4 Direct assay kit (Invitrogen) were 
purchased from Fisher Scientific (UK). Human neuroblastoma cell line SH-SY5Y was purchased from 
LGC Standards (UK). Methanol (K 99.8 %) and sodium chloride was obtained from Th. Geyer GmbH 
and Co. KG (Germany). Ultrapure water was collected from the water system SG Ultra Clear 2002 from 
Evoqua Water Technologies LLC (US). Isotonic phosphate buffered saline (PBS) was prepared by 
dissolving 2.38 g of disodium hydrogen phosphate with 0.19 g potassium dihydrogen phosphate and 
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8 g sodium chloride in 1 L of ultrapure water and adjusted with hydrochloric acid and sodium chloride 
to achieve a pH of 7.4 and an osmotic pressure of 290 mOsm/kg.
Electrospun patch manufacture
Electrospun mucoadhesive patches were produced as described by Santocildes et al. 11 with 
modifications. Briefly, the electrospun dope consisted of 10% (w/w) PVP, 12.5% (w/w) Eudragit RS100 
and 10% (w/w) PEO (400 kDa) and amounts of lidocaine base or lidocaine HCl theoretically resulting 
in a 3% (w/w) drug loading in the electrospun patch (i.e. 0.1 g of either lidocaine base or lidocaine HCl 
added to 0.326 g of polymers in the dope solution). In the case of lidocaine HCl the 3% (w/w) loading 
includes the salt content. Polymers and drug were dissolved in 97% (w/w) ethanol prepared in 
deionised water, and solutions mixed at room temperature using a magnetic stirrer for 24 h or until 
they had dissolved. The electrospinning rig was configured with the following parameters: 19 kV 
voltage, 14 cm tip-to-collector distance and 1.5 mL h-1 flow rate. Additionally, 10% (w/w) PCL dissolved 
in DCM:DMF in a ratio of 93:7 (w/w) was electrospun using the same conditions and used as a backing 
layer 11. The dual layer patch was formed by melting the PCL backing layer onto the drug-containing 
mucoadhesive layer by placing the layers between two glass slides followed by incubation at 70 °C for 
5 min.
Characterisation of electrospun patches
The morphology of the different electrospun patches was analysed using scanning electron 
microscopy (SEM). The samples were gold sputtered and imaged using Tescan Vega3 LMU SEM (UK) 
with a high accelerating voltage of 15 kV. The fibre diameters were subsequently measured from the 
SEM images for the non-drug loaded and drug-loaded patches (n = 3 patches for each condition, ~35 
fibre measurements per image) using ImageJ software (National Institute of Health, US) 23. Differential 
scanning calorimetry (DSC) was applied using a Pyris 1 calorimeter (Perkin Elmer, US) to determine 
the temperature transitions of the drug- and non-drug-containing electrospun patches. Electrospun 
patches (5 - 9 mg), lidocaine HCl or lidocaine base powders (~ 3 mg) were weighed and placed in 50 
D aluminium pans, and aluminium lids crimped on top. Patches or powders were heated from 25 to 
200 °C at 10 °C min-1. The pH was measured after fully dissolving the different electrospun patches (n 
= 3 patches for each condition, 110 ± 4 mg; mean ± SD) in 10 mL of deionised water using a FiveGo pH 
meter (Mettler Toledo, Switzerland) at 20.5°C.
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Quantification of lidocaine
RP-HPLC with UV detection was performed to detect the presence of lidocaine using a XBridge BEH-
C18 column (4.6 mm x 250 mm; 130 Å pore size) (Waters, UK) and a mobile phase composed of 
ACN:water (1:1, v/v) containing 0.1% (v/v) 7.5 M ammonia, with a flow rate of 1 mL min-1, wavelength 
262 nm, a 20 D injection volume, and at room temperature. The retention time of lidocaine was 10.1 
min, and the method was validated in terms of linearity and precision using lidocaine HCl in PBS 
standards of known concentrations. Good linearity  (R2=1.00) was determined with repeat injections 
of lidocaine HCl in PBS ranging from 39 to 1250 D  where previous lower range concentration 
injections determined 1.8 D as the limit of quantitation (ten times the background reading created 
by PBS in the lidocaine peak region).
Dosage uniformity of lidocaine in the electrospun patches
Electrospun patches containing lidocaine HCl or lidocaine base were weighed, dissolved in 1 mL 99.8% 
ethanol with stirring, and analysed by UV RP-HPLC. Electrospun samples (n=3) were taken from three 
separately spun mats to determine batch variation, where lidocaine HCl patches weighed 6.2 ± 1.2 mg 
and lidocaine base patches weighed 9.3 ± 3.3 mg.
Release of lidocaine from the electrospun patches in buffer 
Electrospun patches (Ø 10 mm) containing lidocaine HCl or lidocaine base were weighed and placed 
in a 12-well plate containing 2 mL PBS. Samples of 200 D were withdrawn every 5 minutes for 1 h, 
with the solution being replaced with fresh buffer each time. The amount of lidocaine released was 
quantified using the RP-HPLC method previously described.
Tissue preparation
Ex vivo porcine buccal mucosa was obtained from healthy experimental control pigs (approximately 
30 kg Danish Landrace/Yorkshire × Durox (D-LY)) (Department of Experimental Medicine, University 
of Copenhagen) and stored at -80°C in cryomedia (40% (w/v) glycerol, 20% (w/v) sucrose in PBS at pH 
7.4 and 290 mOsm/kg) 24. Mucosa was thawed and washed by removal from the cryomedia into 4 °C 
PBS positioned on a 4 °C rotating plate and transferring to fresh PBS 4 times with 10 min incubations. 
The submucosa was trimmed to a thickness of 1011 ± 133 D (mean ± SD, n=10) and mounted onto 
an Ussing slider (P2413, Physiological Instruments Inc., US) with an exposed area of 0.71 cm2. 
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Buccal mucosa permeability study
Permeability studies were performed using modular EM-CSY-8 modified Ussing chambers (Physiologic 
Instruments Inc., US). Receptor chambers were filled with 2 mL PBS (pH 7.4) for all experiments. Donor 
chambers either contained 2 mL PBS with 3% (w/v) lidocaine HCl (pH 6.8) or were left empty for 
lidocaine-containing electrospun patch experiments. Patches were punched from the dual-layer 
electrospun mats (Ø 10 mm) and the drug-containing side of the patch was placed on the buccal 
epithelium and held in place with Parafilm® M to assure direct contact of the patch with the tissue for 
the duration of the experiment (Fig. 1). The dual layer patches containing lidocaine HCl weighed 15.6 
mg ± 2.3 mg (mean ± SD, n=10), where the backing membrane PCL layer weighed 3.2 mg ± 0.14 mg 
(mean ± SD, n=3). Sink conditions were maintained in the receptor chambers. A slight temperature 
increase over the 5 h period was observed (~37.0°C to ~38.4°C).
Figure 1. Preparation of porcine buccal mucosa for the lidocaine diffusion study. A) De-frosted porcine 
buccal mucosa (ruler only associated to this image); B) Buccal mucosa cut to size and stretched across 
the Ussing slider with the epithelium facing up; C) Electrospun patch on the epithelium surface; D) 
Parafilm® M stretched across the sample to hold the electrospun patch in place and sandwiched 
together with the second part of the slider.
Aliquots of 200 µL were taken from the receptor chamber every 15 to 30 min over a 5 h period and 
were replaced with fresh PBS at each time point. The lidocaine concentration of each sample was 
determined using UV-HPLC. The accumulated permeated amount (JSS, D min-1 cm-2) was plotted 
against time (t, min) and the steady state flux (dQ/dt, D min-1), where Q <D@ is the drug concentration, 
[1]
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was determined by taking the linear part of the slope between 180 and 300 min using the equation 
(1) for steady state flux (JSS), where A is the diffusion area (0.71 cm2):  =  × 1
For lidocaine HCl in PBS the apparent permeability (Papp, cm min-1) was calculated using equation (2):  =    
  
Where the donor concentration was Cdonor <DL@.
Spatial location of lidocaine in buccal mucosal using MALDI-MSI
Buccal mucosa was thawed, cut to a thickness of approximately 5 mm and mounted onto Ussing 
sliders. Three different experimental conditions were imposed on mounted tissues: 1) 70 µL 0.3% 
(w/v) lidocaine HCl in PBS directly pipetted onto the epithelium; 2) an electrospun patch containing 
lidocaine HCl applied to the epithelium and held in place using Parafilm® M; 3) an electrospun patch 
containing lidocaine base applied to the epithelium and held in place using Parafilm® M. Three tissues 
for each condition were prepared and the sliders were placed in a high humidity chamber filled at the 
bottom with PBS to cover the connective tissue side and incubated at 37.4 °C. Tissues were removed 
from the chamber after 15 min, 1 and 3 h. Samples were immediately embedded in 5% (w/v) CMC and 
stored at -80°C. Frozen tissue samples were mounted in a Leica CM 3050 S Cryostat (Leica 
Microsystems A/S, Germany), cut vertically at -20 °C into 30 D thick cross-sections, thaw-mounted 
onto glass microscope slides that were stored at -80°C. Sections were removed from -80°C and thawed 
using a vacuum desiccator for 5 to 10 min then 300 D of matrix solution (30 mg mL-1 2,5-
dihydroxybenzoic acid (DHB) in methanol:water (1:1, v/v) with 1% (v/v) TFA was sprayed onto the 
sample at a flow rate of 30 D min-1 with a nebulised gas pressure of 2 bar while the sample was 
rotating at 550 rpm, approximately 10 cm from the syringe tip. An AP-SMALDI10 Ion source (TransMIT 
Gesellschaft für Technologietransfer GmbH, Germany) mounted on a QExactive Orbitrap mass 
spectrometer (Thermo Scientific GmbH, Germany) was used for MALDI imaging. Imaging was 
performed in positive ion mode using a scan range of m/z 200-800 and mass resolving power of 
140,000@m/z200. A peak from the DHB matrix at m/z-value 295.02131 was used as a lock mass, 
thereby ensuring a mass accuracy of at least 2 ppm throughout the entire image. The images were 
acquired with a pixel size of 20 D and no oversampling took place (no overlapping between adjacent 
[2]
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ablation craters was confirmed by reflected light microscopy of the samples subsequently to the 
MALDI imaging experiment). The raw data were converted to imzML files 25 and the MALDI images 
was generated in MSiReader v. 0.09 26 using a bin width of 0.002 Th.
Histological staining 
Post-MSI the DHB matrix was removed by washing with ethanol and tissue sections stained with 
haematoxylin and eosin as previously described, 27 then imaged using an Olympus BH-2 microscope 
(Olympus, Japan) equipped with an AxioCam ERc5s camera (Zeiss, Germany).
Lidocaine functional assay
The human neuroblastoma cell line SH-SY5Y was cultured in 1:1 (v/v) DMEM/Hams F12, 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1% non-essential amino acids, 100 IU/mL 
penicillin and 100 DL streptomycin and incubated at 37°C, 5% CO2 in a humidified environment. 
Prior to experiments, cells were loaded with the fluorescent calcium indicator, Fluo-4 Direct 
following the manufacturers instructions. Briefly, cells were removed from tissue culture flasks using 
EDTA, centrifuged and resuspended at 106 cells/mL in Fluo-4 Direct calcium buffer for 30 min at 37°C. 
To test lidocaine bioactivity, lidocaine HCl-loaded or placebo electrospun patches (containing no 
lidocaine) were cut to 2 × 2 cm2 and fully dissolved in 2 mL PBS for 30 min, filter sterilised, then the 
solution added to Fluo-4 Direct-loaded cells to give a final concentration of 0.5 mM lidocaine or 
placebo control and the cells incubated for a further 30 min at room temperature. To determine cell 
calcium responses, fluorescence was measured at 488 nm excitation and 530 /30 nm emission using 
a FACSCaliburTM (BD Biosciences, US). For each sample, baseline fluorescence was measured for 40 s 
then veratridine or vehicle control DMSO was added and the fluorescence response measured for 
approximately a further 160 s. Relative fluorescence units (RFU) were calculated by subtracting the 
baseline median fluorescence intensity from the maximal median fluorescence intensity following 
stimulation with veratridine. 
Results
Manufacture of the electrospun patches
Mucoadhesive electrospun patches containing lidocaine or lidocaine HCl were produced by 
modification of our published protocol 11. SEM was used to determine if the inclusion of lidocaine 
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affected the structure or morphology of the patches (Fig. 2). Patches of three different conditions 
were manufactured; patches containing lidocaine HCl or lidocaine base along with control patches 
without drug. SEM images show that there was no significant difference in fibre diameter or fibre 
structure between drug-containing and drug-free patches (Fig. 2). All patches showed a similar range 
of fibre diameters with a random alignment, where the drug-free fibre diameters ranged from 2.28 ± 
1.35 D  the lidocaine HCl loaded fibres from 1.98 ± 1.50 D and the lidocaine base loaded fibres 
from 2.42 ± 2.09 D (~100 fibres in total measured from n=3 patches; mean ± SD). As two different 
drug compositions are incorporated into the patches, and drug release can be dependent on the pH 
microenvironment of a system, the pH of the patches dissolved in deionised water was measured. It 
was found that the pH of the non-drug containing patches in water was 7.78 ± 0.03, the pH of lidocaine 
HCl containing patches in water was 7.25 ± 0.04 and the pH for the lidocaine base containing patches 
in water was 8.26 ± 0.13 (n=3; mean ± SD).
Figure 2.  Representative SEM images of electrospun patches from n=3 batches where A) is the drug-
free patch, B) patch loaded with 3% (w/w) lidocaine HCl, and C) patch loaded with 3% (w/w) lidocaine 
base.
Lidocaine content of the electrospun patches
Lidocaine was added to the polymer dope to achieve a drug loading of 3% (w/w). As low molecular 
weight species can be lost during spinning 28,29, the content of lidocaine in the patches was determined 
by HPLC. Some variation in the total drug content between patches was observed, with patches 
containing 2.4% ± 0.5% (w/w) lidocaine HCl or 2.5% ± 0.2% (w/w) lidocaine base (n=3). Drug solubility 
for improved bioavailability is of great importance in drug delivery and this may be improved by 
developing high-energy amorphous systems 30. In this case, the drug is encapsulated in polymer fibres 
and needs to be released prior to penetration into the tissue. DSC analysis showed that the respective 
active pharmaceutical ingredients are in an amorphous form within the electrospun fibres (Fig. 3). 
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That is, data showed the absence of a peak at 81°C in the lidocaine HCl-containing patch, where 
lidocaine HCl powder has its melting peak, and the absence of a peak at 70°C, for the lidocaine base-
containing patch, the melting peak of lidocaine base powder. 
 
Figure 3.  DSC heating profiles of A) an empty pan, B) lidocaine HCl powder, C) lidocaine base powder, 
D) PVP/RS100/PEO electrospun fibres, E) PVP/RS100/PEO electrospun fibres containing lidocaine HCl 
and F) PVP/RS100/PEO electrospun fibres containing lidocaine base. The onset melting temperatures 
of the upward facing enthalpy peaks are given to the nearest 0.1°C. The image is representative of n=2 
independent experiments.
Release of lidocaine from the electrospun patches into buffer
The mean accumulative release of lidocaine HCl and lidocaine base from four electrospun patches for 
each condition over one hour is shown in Fig. 4, with respective patch weights of 10.8 ± 3.8 mg and 
11.20 ± 2.7 mg (mean ± SD). As there was variation in patch weight and variation in drug loading the 
drug release per 10 mg of patch was calculated. Lidocaine release from the lidocaine HCl patches 
increased rapidly to 0.16 ± 0.04 mg (mean ± SD) over the first 15 min, then gradually at 0.21 ± 0.02 mg 
up to 60 min. In contrast, release of lidocaine base was slower, 0.06 ± 0.01 mg within 15 min, gradually 
increasing to 0.11 ± 0.02 mg after 1 h (Fig. 4). Overall, the release of lidocaine from the lidocaine HCl 
patches was significantly quicker than that of lidocaine base from electrospun patches (p<0.0001; 
Mann-Whitney U test 31).
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Figure 4. Accumulative release of lidocaine from the lidocaine HCl-or lidocaine base  containing 
electrospun patches in PBS over 1 h, shown as drug released in mg per 10 mg of patch. Data presented 
is the mean ± SD (n=4).
Permeation of lidocaine HCl through ex vivo porcine buccal mucosa
Dual layer electrospun patches were used for buccal mucosal permeation studies ex vivo to ensure 
uni-directional release of lidocaine directly into the mucosal tissue, thereby preventing release into 
the donor chamber. Accumulative permeation of lidocaine from patches containing between 0.20 mg 
to 0.35 mg of lidocaine HCl per patch was linear over a 5 h period (Fig. 5), resulting in a flux of 0.268 ± 
0.009 D cm-2 min-1 (mean ± SD; n= 6). In comparison, application of 3% (w/v) lidocaine HCl in solution 
resulted in a flux of 4.092 ± 0.062 D cm-2 min-1 and Papp value of 136.4 ± 0.002 (× 10-3) cm-2 min-1 (mean 
± SD; n= 4) (Supplementary 1). However, no lidocaine could be detected in the receptor buffer upon 
application of electrospun patches containing 0.25 mg to 0.39 mg lidocaine base per patch.
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Figure 5. Accumulative permeation of lidocaine released from an electrospun patch through ex vivo 
porcine buccal mucosa. The electrospun patches contained between 0.20 to 0.35 mg lidocaine HCl. 
Data are mean ± SD (n=6).
Spatial distribution of lidocaine HCl and lidocaine base released from electrospun patches applied 
to ex vivo porcine buccal mucosa using MALDI-MSI
Time-dependent drug penetration and localisation using MALDI-MSI was first investigated by 
exposure to a solution of lidocaine HCl (3 mg mL-1, approximately 0.21 mg applied) for up to 3 h (Fig. 
6). The control image with no lidocaine applied to the tissue, shows that the lidocaine m/z signal is not 
present in the tissue. After 15 min, lidocaine was located exclusively in the stratified epithelium, where 
it was evenly distributed and extending into the rete ridges. Drug penetration did not progress beyond 
the basement membrane. In contrast, after 1 h, lidocaine was concentrated throughout the entire 
epithelium and was observed progressing into the lamina propria (Fig. 6), and by 3 h, lidocaine was 
found evenly distributed throughout the epithelium, lamina propria and submucosa (Fig. 6). The mass 
spectrum averaged over 100 pixels from this 3 h time point (Fig. 6) is given in Supplementary 2, to 
show that the lidocaine signal was best detected in the protonated form at m/z 235.1807 with a mass 
accuracy of 1.0 ppm.  
Lidocaine released from the lidocaine HCl patches was visible in the stratified epithelium and 
extending into the lamina propria after just 15 min (Fig. 7). After 1 h and 3 h, lidocaine was distributed 
throughout the epithelium and lamina propria (Fig. 7). The mucosal distribution of lidocaine was more 
widespread and homogeneous when lidocaine HCl was applied as a solution compared to the 
electrospun patches (Fig. 6). However, unlike administration of a solution in the oral cavity, the 
electrospun patches maintained local contact to the tissue where lidocaine was not depleted from the 
patch over a period of 3 h (Fig. 7). Similar spatial distribution of lidocaine in tissue was observed from 
lidocaine base-containing patches applied to ex vivo buccal tissue (Supplementary 3).
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 Figure 6. Hematoxylin and eosin (H&E) stained tissue sections and corresponding MALDI-MS images 
of porcine buccal mucosa as a control with no treatment and exposed to 0.3% (w/v) lidocaine HCl 
solution (m/z 235.1805 [M+Na]+; red) after 15 min, 1 h and 3 h. The epithelium (blue) for each sample 
is shown using the epithelial marker lipid phosphatidylglycerol (34:1) (m/z 771.5140 [M+Na]+).
Page 15 of 26
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 7. Hematoxylin and eosin (H&E)  stained tissue sections and corresponding MALDI-MS images 
of porcine buccal mucosa exposed to dual-layer electrospun patches containing 3% (w/v) lidocaine 
HCl (m/z 235.1805 [M+Na]+; red) after 15 min, 1 h and 3 h. The epithelium (blue) for each sample is 
shown using the epithelial marker lipid phosphatidylglycerol (34:1) (m/z 771.5140 [M+Na]+). The 
arrows in the H&E images show the position of the electrospun patch.
Lidocaine released from electrospun patches blocks voltage-gated sodium channels and prevents 
veratridine-induced calcium responses in SH-SY5Y neuroblastoma cells
Veratridine, an alkaloid toxin found in Liliacae plants, causes persistent opening of voltage-gated 
sodium channels leading to cell depolarization and downstream intracellular calcium flux 32. Lidocaine 
has been shown to exert its biological action by blocking these voltage-gated sodium channels 33. To 
test whether the lidocaine released from electrospun patches remained functional, we examined its 
ability to block endogenously expressed voltage-gated sodium channels by examining intracellular 
calcium flux following cell stimulation with veratridine. Untreated SH-SY5Y cells displayed increased 
fluorescence associated with intracellular calcium flux when stimulated with veratridine (17.9 ± 2.8 
RFU over baseline; Fig. 8A). Similar data were observed when SH-SY5Y cells were pre-treated with the 
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elutant from the placebo electrospun patches that contained no lidocaine (19.4 ± 3.0 RFU over 
baseline, Fig. 8B). In contrast, intracellular calcium flux was significantly reduced (11.3 ± 4.8 RFU over 
baseline; `//;@ compared to the placebo patch when cells were pre-incubated with the elutant from 
lidocaine HCl electrospun patches (Fig. 8C&D), showing that the lidocaine released from the 
electrospun patches was functional and able to inhibit veratridine-mediated opening of voltage-gated 
sodium channels. Injection of DMSO alone as control did not induce a calcium flux fluorescence signal, 
whilst pre-incubation of cells with a solution of lidocaine HCl (10 mM) inhibited the veratridine-
mediated calcium influx by 88% (2.2 ± 1.5 RFU over baseline; `//;@
Figure 8. Calcium flux in SH-SY5Y cells was determined overtime using flow cytometry. Baseline 
fluorescence was acquired for 40 s before injection of veratridine (black arrow) to induce a calcium 
influx.  A) Veratridine alone (control), B) placebo patch elutant and C) lidocaine HCl patch elutant (0.5 
mM). Relative fluorescent units were determined by subtracting the median baseline from the 
maximum median fluorescence following stimulation with veratridine.  Data presented is the mean ± 
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SD (n=3). Data was analysed using a non-parametric one-way ANOVA with a post-hoc Kruskal-Wallis 
multiple comparison test, * `//;
Discussion
Painful oral mucosal conditions and dental pain can greatly affect quality of life. For dental treatments 
injections are commonly used, however this causes dental anxiety in many patients. A number of 
topical delivery methods of pain relief are available 34, although many are inadequate for targeting the 
affected local tissue and delivering a sustained drug release, where mucoadhesiveness and direct 
contact of the delivery vehicle to the local tissue is an underlying issue. We have previously developed 
a mucoadhesive electrospun oral drug delivery patch to resolve these issues and have used these 
patches to deliver the corticosteroid clobetasol-17-propionate to mucosal tissue 11,12. Incorporation of 
lidocaine into electrospun polymers for transbuccal delivery has not previously been performed, 
although Palo et al. incorporated lidocaine HCl into an ink-jet printed oral patch in a combined 
electrospun additive manufacturing process 35, thus not directly comparable to the patches used in 
this study. The data reported here confirms the ability of applying electrospinning to manufacture 
patches consisting of microscale polymer fibres loaded with lidocaine HCl and lidocaine base during 
fabrication. The incorporation of lidocaine HCl or base did not appear to influence fibre morphology, 
consistent with previous reports for unloaded and drug-loaded fibres 12,36. DSC analysis showed that 
both forms of lidocaine were amorphous when incorporated into electrospun fibres. Similar 
observations have been reported for many other drug compounds where the amorphous form has 
been shown to aid drug solubility and bioavailability 3739.
Following the manufacture of lidocaine-loaded patches, drug release studies were performed to 
compare release rates for lidocaine HCl or lidocaine base patches (Fig. 4). Significantly greater 
lidocaine release was observed from lidocaine HCl-containing patches.  Around 80% of lidocaine was 
released from the electrospun fibres in 1 h, which is similar to previously reported release of lidocaine 
from poly-L-lactic acid electrospun fibres containing lidocaine HCl 40. Lidocaine base has been 
previously electrospun into CMC/PEO fibres 41, where release in the first hour was close to 50%, also 
agreeing with the findings in this study. One reason for the difference in release between the two drug 
compositions may be the surface pH microenvironment of the electrospun patches, and the difference 
in acidity between the encapsulated lidocaine HCl and base. The acidic lidocaine HCl protonates and 
releases more quickly than lidocaine base as shown in this study. The solubility of weakly basic drugs 
increases in lower pH environments and hence acidity modifiers within the delivery vehicle may be 
used to increase their solubility 42.
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The lidocaine-loaded electrospun patches were subsequently investigated for their ability to deliver 
lidocaine to porcine buccal mucosa. For this experiment cryopreserved frozen porcine buccal mucosa 
was used, as previous studies have shown no change in the permeability barrier functions between 
fresh and frozen mucosal tissue 7,24. The permeation profile of lidocaine across porcine buccal mucosa 
released from a lidocaine HCl-containing patch had a similar linear profile with a slight time lag as 
observed for lidocaine permeating oesophageal porcine tissue 7 and rabbit ear skin 43,44 after release 
from a lidocaine HCl-containing polyvinyl alcohol film. The lidocaine apparent permeability coefficient 
in solution to cross porcine buccal epithelium has been previously reported as 17.0 ± 1.8 (× 10-6) cm s-1, 
which is seven times greater than shown in this study 17. However, here we have used a thicker section 
of mucosal tissue containing both epithelium and lamina propria compared to that study by Kokate et 
al. In the present study, lidocaine released from lidocaine base patches was not detected in the 
receptor chamber, suggesting that lidocaine release from the electrospun fibres was too slow and/or 
the amount of permeated lidocaine through the tissue was too low to be detected by RP-HPLC. 
Lidocaine base has previously been reported to permeate buccal tissue when released from a 
polymeric thin film 45, likely because the film contained approximately 100 times more lidocaine than 
in this study. Notably, the permeation of lidocaine observed in the study by Cavallari et al. was 
surprisingly quick as the authors were able to detect the drug in the receptor chamber after only 5 
min and permeation was shown to be at a similar rate to its release rate in PBS despite the tissue 
thickness being reported to be 1.3 cm 45.
While ex vivo permeation studies provide valuable information on the rate of permeation, these 
experiments do not provide information on the spatial localisation of drugs within tissue over time. 
MSI is a powerful tool for high-resolution detection of substances in tissue sections and a number of 
MSI techniques have been used to detect the presence of lidocaine, and metabolites thereof, in skin 
4648. Here, we show for the first time the spatial distribution of lidocaine within porcine buccal mucosa 
following delivery from a mucoadhesive electrospun patch. Our data shows that lidocaine penetration 
into the oral tissue is most pronounced in the region of patch placement, especially in the first 15 min 
where lidocaine was mainly present in the stratified epithelium directly adjacent to the patch. For the 
lidocaine HCl-containing patches, the lidocaine signal was most intense within the electrospun patch 
compared to the tissue, especially for 15 min and 1 h. When associating this to the lidocaine 
permeation data where only 20 D of potentially up to 300 D of lidocaine contained in the patch had 
permeated through the mucosa after 1 h, it is understandable that the signal in the patch is much 
stronger. Once released from the patch, lidocaine, being a lipophilic molecule, permeated through the 
epithelium and into the lamina propria over time that was consistent with the homogeneous time-
dependent tissue distribution displayed by lidocaine HCl in solution. The tissue penetration depth may 
Page 19 of 26
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
also be dose-dependent, as has been shown previously following application of lidocaine to skin 47. 
MALDI-MSI also allowed us to review the localisation of lidocaine released from the lidocaine base-
containing patches (Supplementary 3). Although lidocaine permeation was below the detection limit 
by HPLC, we found that lidocaine was localised throughout the epithelium and in the lamina propria 
after just 15 min exposure to the patch. 
Although previous studies have shown release of lidocaine from a number of fabricated films, none 
have shown that the drug retains its functional biological activity once released. Lidocaine exerts its 
anaesthetic activity by blocking several voltage-gated sodium channels expressed by neuronal cells 33. 
Here, we show that lidocaine released from electrospun patches was able to interact with voltage-
gated sodium channels expressed by SH-SY5Y neuroblastoma cells preventing their opening upon 
stimulation veratridine 32. These data give clear evidence that levels of lidocaine released from patches 
directly into tissue are therapeutically active, enabling blockage of oral mucosal neuronal cell 
depolarisation.
Conclusion
Electrospun patches containing lidocaine HCL and lidocaine base were successfully manufactured by 
electrospinning, and the release of biologically active lidocaine from both types of patch was 
demonstrated. Detailed investigations of diffusion through ex vivo porcine buccal mucosa suggested 
that lidocaine permeated into tissues following release from a patch. This was confirmed by MALDI-
MSI where, for the first time, the distribution of electrospun delivered lidocaine within oral soft tissue 
was visualised. These data provide strong evidence that electrospun patches have potential as a 
delivery vehicle for lidocaine into buccal mucosa. Further clinical investigation is required to 
determine the feasibility of using this patch system as a topical dental anaesthetic or as an analgesic 
for patients with painful oral mucosal disease conditions.
Supplementary information
Supporting information is available, describing accumulative permeation of lidocaine HCl 
through porcine buccal mucosa and additional mass spectrometry data.  This is available 
online, and this material is available free of charge via the internet at http://pubs.acs.org.
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